Spots Global Cancer Trial Database for RC48-ADC in HER2-low Advanced Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: RC48-ADC in HER2-low Advanced Breast Cancer
Official Title: Disitamab Vedotin (RC48-ADC) in Patients With HER2-low Advanced Breast Cancer
Study ID: NCT05831878
Conditions
Interventions
Study Description
Brief Summary: To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) as salvage treatment in patients with HER2-low advanced breast cancer who have received up to one previous chemotherapy for recurrent or metastatic disease without previous use of antibody-drug conjugate.
Detailed Description: Subjects with HER2-low advanced breast cancer were treated with Disitamab vedotin as salvage treatment. ORR, PFS, OS and AE were assessed during the trial. HER2-low status is defined as IHC1+ or IHC2+ with negative FISH test.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, , China
Contact Details
Name: Wenjin Yin, M.D.
Affiliation: Renji Hospital,School of Medicine, Shanghai Jiaotong University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
